Adrenocortical Carcinoma Market

Table of Content

1. INTRODUCTION
   1. Study Assumptions and Market Definition
   2. Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
   1. Market Overview
   2. Market Drivers
      1. Rise in the Prevalence of Rare Cancers
   3. Market Restraints
      1. Limited Treatment Options
      2. Low Disease Awareness and Diagnosis Challenges
   4. Market Opportunities
      1. Increasing Focus of Companies on the Treatment of Adrenocortical Carcinoma
   5. Market Trends
      1. Emergence of Immunotherapy
      2. Growing Emphasis on Precision Medicine
5. MARKET SEGMENTATION
   1. By Type
      1. Localized Adrenocortical Carcinoma
      2. Metastatic Adrenocortical Carcinoma
   2. By Drug Type
      1. Tamoxifen
      2. Mifepristone
      3. Toremifene
      4. Spironolactone
      5. Others
   3. By Treatment
      1. Surgery
      2. Chemotherapy
      3. Targeted Therapy
      4. Radiation Therapy
      5. Biologic Therapy
      6. Others
   4. By Diagnosis
      1. MRI
      2. CT Scan
      3. PET Scan
      4. Biopsy
      5. Others
   5. By End-Users
      1. Clinic
      2. Hospital
      3. Others
   6. By Distribution Channel
      1. Hospital Pharmacy
      2. Retail Pharmacy
      3. Online Pharmacy
   7. By Key Geographic Regions
      1. North America
         1. United States
         2. Canada
         3. Mexico
      2. Europe
         1. Germany
         2. United Kingdom
         3. France
         4. Italy
         5. Spain
         6. Rest of Europe
      3. Asia Pacific
         1. China
         2. Japan
         3. India
         4. Australia
         5. South Korea
         6. Rest of Asia Pacific
      4. Middle East and Africa
         1. GCC
         2. South Africa
         3. Rest of Middle East and Africa
      5. South America
         1. Brazil
         2. Argentina
         3. Rest of South America
6. COMPETITIVE LANDSCAPE
   1. Company Profile
      1. Bristol-Myers Squibb Company
      2. DIGIRAD CORPORATION
      3. EnGeneIC Ltd.
      4. Exelixis, Inc.
      5. Fresenius Kabi AG
      6. GENERAL ELECTRIC COMPANY
      7. Hitachi, Ltd.
      8. HRA Pharma
      9. Integra LifeSciences
      10. Merck Sharp & Dohme Corp.
      11. Mylan N.V.
      12. NeuroLogica Corp.
      13. ORPHAGEN PHARMACEUTICALS
      14. Pfizer Inc.
      15. SinoVision
      16. Tempest Therapeutics, Inc.
      17. WG Critical Care, LLC
      18. Zimmer Biomet
   2. MARKET OPPORTUNITIES AND FUTURE TRENDS

Frequently Asked Questions

Q.1. What is the projected market value of the global Adrenocortical Carcinomamarket?

The global market of Adrenocortical Carcinoma is projected to reach USD 860.6 Mn by 2033.

Q.2. What is the estimated growth rate (CAGR) of the global Adrenocortical Carcinomamarket?

The global Adrenocortical Carcinoma market has an estimated annual growth rate of 2.5%. 

Q.3. What are the recent trends of Adrenocortical Carcinomamarket?

Emergence of immunotherapy and growing emphasis on precision medicine are some of the major trends of the market that is projected to boost the market growth in the near future.

Q.4. Which are the top companies to hold the market share in Adrenocortical Carcinoma?

The major companies profiled in this report include Bristol-Myers Squibb Company, DIGIRAD CORPORATION, EnGeneIC Ltd, Exelixis, Inc, Fresenius Kabi AG, GENERAL ELECTRIC COMPANY, Hitachi, Ltd., HRA Pharma, Integra LifeSciences, Merck Sharp & Dohme Corp., Mylan N.V., NeuroLogica Corp., ORPHAGEN PHARMACEUTICALS, Pfizer Inc., SinoVision, Tempest Therapeutics, Inc., WG Critical Care, LLC, Zimmer Biomet, among others.

Q.5. Which region is estimated to held highest CAGR inAdrenocortical Carcinomamarket?

North America is estimated to hold biggest share in the market for Adrenocortical Carcinoma.